Compare Mesoblast Limited (MESO) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Norfolk Southern Corporation — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Norfolk Southern Corporation trades at $317.24 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 40.7× Mesoblast Limited's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Norfolk Southern Corporation for 33 Days on average.
| MESO | NSC | |
|---|---|---|
Market Cap | $1.75B | $71.20B |
Volume | 239,027 | 555,248 |
Sector | Health | Industrials |
52-Week High | $20.96 | $352.98 |
52-Week Low | $13.19 | $278.19 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $1.83B | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
